ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail

ClinicalTrials.gov ID: NCT01302119

Public ClinicalTrials.gov record NCT01302119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 23, 2026, 7:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults

Study identification

NCT ID
NCT01302119
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
604 participants

Conditions and interventions

Interventions

  • AN2690 Topical Solution, 5% Drug
  • Solution Vehicle Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2011
Primary completion
Dec 30, 2012
Completion
Feb 19, 2013
Last update posted
Apr 2, 2019

2011 – 2013

United States locations

U.S. sites
26
U.S. states
18
U.S. cities
25
Facility City State ZIP Site status
Investigational Site Phoenix Arizona 85050
Investigational Site Novato California 94945
Investigational Site Oceanside California 92056
Investigational Site San Diego California 92123
Investigational Site San Francisco California 94115
Investigational Site Santa Rosa California 95405
Investigational Site Miami Florida 33144
Investigational Site Miami Florida 33175
Investigational Site Nampa Idaho 83642
Investigational Site Evansville Indiana 47714
Investigational Site Ann Arbor Michigan 48103
Investigational Site St Louis Missouri 63117
Investigational Site Verona New Jersey 07044
Investigational Site Albuquerque New Mexico 87106
Investigational Site High Point North Carolina 27262
Investigational Site Raleigh North Carolina 27612
Investigational Site Columbus Ohio 43212
Investigational Site Portland Oregon 97223
Investigational Site Philadelphia Pennsylvania 19103
Investigational Site Greer South Carolina 29651
Investigational Site Knoxville Tennessee 37922
Investigational Site Dallas Texas 75243
Investigational Site San Antonio Texas 78209
Investigational Site Salt Lake City Utah 84124
Investigational Site Harrisonburg Virginia 22801
Investigational Site Norfolk Virginia 23507

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01302119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 2, 2019 · Synced Apr 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01302119 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →